BharatNotes What is Biosimilars?
A biosimilar is a biological medicine that is highly similar to an already-licensed biologic (the "reference product"), with no clinically meaningful differences in safety, purity and potency. Unlike a chemical generic, which is an exact copy of a small-molecule drug, a biosimilar can never be identical to its reference product because biologics are large, structurally complex molecules manufactured inside living cells, where natural batch-to-batch variation is unavoidable. In India, the official term used by regulators is "similar biologic".
Biosimilar vs. Generic — the key distinction
| Feature | Generic drug | Biosimilar |
|---|---|---|
| Source | Chemically synthesised | Produced in living systems (cells, microbes) |
| Molecular size | Small, simple | Large, complex |
| Copy standard | Identical, bioequivalent | "Highly similar", comparability-based |
| Approval data | No new clinical trials needed | Extensive comparative quality, preclinical and clinical studies |
| Development cost | Low | High (years of comparability work) |
Regulatory pathways
- India: Regulated jointly by the CDSCO (Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare) and the Department of Biotechnology through its Review Committee on Genetic Manipulation (RCGM). The "Guidelines on Similar Biologics" were first issued in 2012 and revised in 2016 to align the approval pathway with international standards.
- United States: The Biologics Price Competition and Innovation Act (BPCIA), 2009 (enacted as part of the Affordable Care Act, March 2010) created the abbreviated section 351(k) licensure pathway. The FDA also recognises a higher "interchangeable" status, allowing pharmacist-level substitution without the prescriber's permission.
- European Union: The EMA established the world's first biosimilar framework, approving Omnitrope (somatropin) in April 2006.
India's position
India is widely regarded as a global leader in biosimilars. It approved a biosimilar (for hepatitis B) as early as 2000 — ahead of both Europe and the US — and Reditux (a rituximab biosimilar by Dr Reddy's, launched in 2007) was the first rituximab biosimilar in the world, introduced at roughly half the originator's price and dramatically expanding patient access. Industry trackers reported that India had approved well over 100 biosimilars by early 2025 (industry estimate, ~135 as of Jan 2025) — among the highest of any country, though figures vary by source.
Significance
- Affordable healthcare: Biosimilars lower the cost of expensive biologic therapies for cancer, diabetes and autoimmune diseases, advancing the goal of accessible treatment.
- Industry & exports: They strengthen India's "pharmacy of the world" position and high-value biopharma exports.
- Patent cliff: As blockbuster biologics lose patent protection, biosimilars open large markets while raising IPR and data-exclusivity debates.
UPSC angle
Foundation concept — no direct PYQ on the exact term, but it underpins recurring GS3 questions on biotechnology, drug regulation, IPR and affordable healthcare. Aspirants should remember: biosimilar ≠ generic, and the dual Indian regulators (CDSCO + DBT/RCGM).
